OCT-598

N/A

Report date: 2026/01/23 20:01:08
NME

Base Information

Drug NameOCT-598
Drug Alias NameKNP-502OCT-598OCT-3598
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP4 receptor antagonistsProstanoid EP2 receptor antagonists
TargetsProstanoid EP2 receptorProstanoid EP4 receptor
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKanaph Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKanaph Therapeutics IncOscotec Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A